Endo Health Solutions (Nasdaq: ENDP) today announced that NuPathe Inc. (NASDAQ: PATH) has terminated its merger agreement with Endo. Endo has received a $5 million termination fee from NuPathe. "We believe that the agreement NuPathe has ...
American Medical Systems, a subsidiary of Endo Health Solutions, has obtained CE Mark approval for its RetroArc retropubic sling system, designed to treat female stress urinary incontinence (SUI). In collaboration with leading physicians, ...
The US Food and Drug Administration (FDA) has accepted for review the complete response submission made by Endo Health Solutions' subsidiary Endo Pharmaceuticals to the new drug application (NDA) for its testosterone undecanoate injection ...
Tags: Aveed Injection, Medicine
Specialty pharmaceutical company Actavis has won FDA approval for abbreviated new drug application (ANDA) of generic equivalent to Endo Health Solutions' Opana ER. Oxymorphone Hydrochloride extended-release tablets, which is available in ...
Tags: FDA, ANDA, Generic Opana ER
Endo Pharmaceuticals has unveiled 7.5mg and 15mg strengths of the reformulated version of OPANA ER with INTAC technology designed to be crush-resistant. The launch makes all the approved strengths of the reformulated version product ...
Tags: Endo, OPANA ER, INTAC technology, 7.5mg and 15mg strengths
American Medical Systems (AMS), an Endo Health Solutions company, and Allergan have entered into an agreement to jointly develop and seek regulatory approval for the delivery of Botox (onabotulinumtoxinA) using the JetTouch system. ...
Tags: AMS, JetTouch system, medical application
Qualitest Pharmaceuticals has introduced generic version of Singulair (montelukast sodium) tablets and chewable tablets and will immediately begin the product shipment. The launch of the Montelukast Sodium Tablets indicated for treating ...
Tags: Generic Singulair Tablets, Chewable Tablets, Endo Health Solutions
BioDelivery Sciences International, a developer of drug delivery technologies, and Endo Health Solutions have started enrolling patients for its Phase 3 clinical program of BEMA Buprenorphine, designed as a treatment for moderate to severe ...
Tags: BioDelivery Sciences International, Endo Health Solutions